Beovu Injection
Generic name:brolucizumab
Dosage form: injection, solution
Drug class:Anti-angiogenic ophthalmic agents
Medically reviewed by Drugs.com. Last updated on May 1, 2022.
On This Page
- Indications and Usage
- Dosage and Administration
- Dosage Forms and Strengths
- Contraindications
- Warnings and Precautions
- Adverse Reactions/Side Effects
- Use In Specific Populations
- Description
- Clinical Pharmacology
- Nonclinical Toxicology
- Clinical Studies
- How Supplied/Storage and Handling
- Patient Counseling Information
INDICATIONS AND USAGE
BEOVU® is indicated for the treatment of:
Neovascular (Wet) Age-related Macular Degeneration (AMD)
1.2 Diabetic Macular Edema (DME)
DOSAGE AND ADMINISTRATION
General Dosing Information
For ophthalmic intravitreal injection. BEOVU must be administered by a qualified physician.
BEOVU is available packaged as follows [see How Supplied/Storage and Handling (16)]:
- Pre-filled Syringe
- Vial kit with injection components (vial, filter needle)
Neovascular (Wet) Age-Related Macular Degeneration (AMD)
The recommended dose for BEOVU is 6 mg (0.05 mL of 120 mg/mL solution) administered by intravitreal injection monthly (approximately every 25 to 31 days) for the first three doses, followed by 6 mg (0.05 mL) by intravitreal injection once every 8 to 12 weeks.
2.3 Diabetic Macular Edema (DME)
The recommended dose for BEOVU is 6 mg (0.05 mL of 120 mg/mL solution) administered by intravitreal injection every six weeks (approximately every 39-45 days) for the first five doses, followed by 6 mg (0.05 mL) by intravitreal injection once every 8-12 weeks.
2.4 Preparation for Administration – Pre-filled Syringe and Vial
 | Store BEOVU in the refrigerator between 2°C to 8°C (36°F to 46°F); do not freeze. Keep BEOVU in the outer carton to protect from light. |
 | Prior to use, the unopened glass vial or sealed blister pack of BEOVU may be kept at room temperature, 20°C to 25°C (6...
MEDICAL DEPARTMENTS
Cardiology
Pediatrics
Diabetes Care
Pre-natal Care
Ultrasound Echocardiogram
|
